Wells Fargo & Company Begins Coverage on Merus (NASDAQ:MRUS)

Wells Fargo & Company started coverage on shares of Merus (NASDAQ:MRUS) in a research report sent to investors on Friday, MarketBeat.com reports. The firm issued an overweight rating and a $91.00 price objective on the biotechnology company’s stock.

MRUS has been the subject of several other reports. The Goldman Sachs Group began coverage on shares of Merus in a research report on Thursday, November 21st. They set a “buy” rating and a $73.00 price objective for the company. UBS Group assumed coverage on Merus in a report on Thursday, October 24th. They set a “buy” rating and a $72.00 price target for the company. Needham & Company LLC reaffirmed a “buy” rating and issued a $85.00 price objective on shares of Merus in a report on Monday, December 9th. HC Wainwright reiterated a “buy” rating and set a $85.00 price objective on shares of Merus in a research report on Monday, December 2nd. Finally, Guggenheim reissued a “buy” rating and issued a $109.00 target price (down previously from $111.00) on shares of Merus in a research report on Tuesday, December 3rd. One research analyst has rated the stock with a sell rating, thirteen have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $86.08.

Merus Stock Down 0.7 %

Shares of NASDAQ MRUS opened at $41.25 on Friday. The business’s 50 day moving average price is $42.10 and its two-hundred day moving average price is $47.61. The company has a market cap of $2.82 billion, a PE ratio of -10.44 and a beta of 1.11. Merus has a twelve month low of $37.66 and a twelve month high of $61.61.

Institutional Investors Weigh In On Merus

Several institutional investors have recently added to or reduced their stakes in MRUS. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in Merus by 17.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 84,200 shares of the biotechnology company’s stock worth $4,207,000 after purchasing an additional 12,212 shares during the period. GSA Capital Partners LLP bought a new position in Merus in the 3rd quarter valued at approximately $675,000. State of New Jersey Common Pension Fund D bought a new stake in shares of Merus in the 3rd quarter worth $1,870,000. US Bancorp DE purchased a new position in shares of Merus in the third quarter worth $103,000. Finally, HighTower Advisors LLC bought a new position in shares of Merus during the third quarter valued at $358,000. Hedge funds and other institutional investors own 96.14% of the company’s stock.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.